Latest News

Add to Favorites Subscribe Share
newswise-fb-share-

Healing and Hope: Treating Fragile X in Serbia

UC Davis MIND Institute

Doctors and scientists — experts in the rare and severely disabling fragile X syndrome — had arrived from the United States, including six from the UC Davis MIND Institute. They came to offer the families useful information and maybe open doors to desperately needed help in a region of the world that, until fairly recently, hardly recognized fragile X syndrome, let alone knew how to diagnose or treat it.

Channels: All Journal News, Autism, Children's Health, Family and Parenting, Healthcare, Neuro,

Released:
23-Jan-2020 1:20 PM EST
Open in New Tab
Comment
Newswise: Cause of gap in starting pay between male and female physicians still inconclusive

Cause of gap in starting pay between male and female physicians still inconclusive

DePaul University

When taking into account factors such as work-life balance, the pay difference between new male and female physicians is still largely unaccounted for, according to findings that were published Jan. 22 ahead of print and will also appear in the February issue of the journal Health Affairs.

Channels: All Journal News, Gender Issues, Healthcare, In the Workplace,

Released:
23-Jan-2020 1:15 PM EST
Open in New Tab
Comment
Feature

Social and Behavioral Sciences

Jefferson4CHP3002.jpg

Oral Hormone-Blocking Drug May Help with Heavy Menstrual Bleeding

Thomas Jefferson University

In women with uterine fibroids, the drug elagolix suppresses ovarian hormone production and prevents heavy menstrual bleeding

Channels: All Journal News, Clinical Trials, Healthcare, OBGYN, Pharmaceuticals, Surgery, Women's Health, NEJM,

Released:
23-Jan-2020 12:50 PM EST
Open in New Tab
Comment
Research Results
Embargo will expire:
28-Jan-2020 11:00 AM EST
Released to reporters:
23-Jan-2020 12:50 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 28-Jan-2020 11:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Research Results
Embargo will expire:
29-Jan-2020 9:00 AM EST
Released to reporters:
23-Jan-2020 12:40 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 29-Jan-2020 9:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Expert Pitch
Newswise: Researchers uncover two-drug combo that halts the growth of cancer cells

Researchers uncover two-drug combo that halts the growth of cancer cells

UT Southwestern Medical Center

UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.

Channels: Cancer, Clinical Trials, Drug Resistance, Healthcare, Pharmaceuticals, National Cancer Institute (NCI), All Journal News,

Released:
23-Jan-2020 12:10 PM EST
Open in New Tab
Comment
Research Results
hms-logo.gif

Adrenaline Handbrake

Harvard Medical School

Researchers have solved the long-standing mystery of how adrenaline regulates a key class of membrane proteins that are responsible for initiating the contraction of heart cells. The findings provide a mechanistic description of how adrenaline stimulates the heart and present new targets for cardiovascular drug discovery, including the potential development of alternative therapeutics to beta-blockers.

Channels: All Journal News, Cardiovascular Health, Cell Biology, Pharmaceuticals, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Nature (journal),

Released:
23-Jan-2020 12:05 PM EST
Open in New Tab
Comment
Research Results
Embargo will expire:
28-Jan-2020 3:05 AM EST
Released to reporters:
23-Jan-2020 11:50 AM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 28-Jan-2020 3:05 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Announcement


0.36747